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Abstract PIWI-interacting RNA (piRNAs), once thought to be mainly functioning in germlines,
are now known to play an essential role in somatic and cancerous tissues. Ping-pong cycle initi-
ation and mitochondria-based phased production constitute the core of the piRNA biogenesis
and these two processes are well conserved in mammals, including humans. By being involved
in DNA methylation, histone marker deposition, mRNA degradation, and protein modification,
piRNAs also contribute to carcinogenesis partly due to oncogenic stress-induced piRNA dysre-
gulation. Also, piRNAs play important roles in cancer stemness, drug resistance, and tumor
immunology. Results from liquid biopsy analysis of piRNA can be used in both cancer diagnoses
and cancer prognoses. A combination of targeting piRNA with other therapeutic strategies
could be groundbreaking cancer treatment.
Copyright ª 2020, Chongqing Medical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Introduction
P-element-induced wimpy testis (PIWI-interacting RNAs
(piRNAs) are the new members of the RNA interference
family. They usually comprise of 21e35 nucleotides (nt)
with a 2ʹ-O-methyl-modified 3ʹ termini and interact spe-
cifically with the PIWI subfamily of Argonaute proteins.1e3
Originally described as repeat-associated siRNAs (rasiR-
NAs), piRNAs mediate the silencing of genomic tandem re-
peats and transposable elements in the D. melanogaster
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germline.4,5 It wasn’t until 2006 when they were found to
interact with PIWI proteins in many other organisms were
they referred as piRNAs.1e3 Since then, there have been
several impactful discoveries made in the piRNA-PIWI field
(Fig. 1a). And their functions have been expanded from the
well-known role of transposon silencing in germline cells to
epigenetic modification or post-transcriptional gene
silencing (PTGS) of protein-coding genes in somatic and
cancerous tissues.6e20
There are a few major differences that distinguish piR-
NAs from miRNAs and siRNAs. For example, as Argonaute
proteins are divided into two subfamilies, the Argonaute
(AGO) and PIWI families, piRNAs bind PIWI subfamily pro-
teins to exert their effects while miRNAs and siRNAs bind
the AGO subfamily proteins.21 In terms of gene regulation,
siRNAs, miRNAs, and piRNAs are known to have the ability
to silence or trigger the degradation of mRNA. Members of
the piRNAs primarily function through epigenetic silencing
in the nucleus although they can conduct miRNA-like tran-
script silencing in the cytoplasm.22,23 piRNAs, 21 to 35 nu-
cleotides (nt)c long, are derived from single strand
precursors generated via a Dicer-independent mechanism.
In contrast, miRNAs and siRNAs, 20 to 24 nt long, are
derived from double-stranded RNA (dsRNA) or stem-loop
precursors processed by Dicer RNase III.24 An additional
distinguishing characteristic is that piRNAs possess 20-O-
methylation at the 30-terminus in a variety of animals while
20-O-methylation in siRNAs and miRNAs are mainly found in
plants, despite a few reports of 20-O-methylated siRNAs in
Drosophila.25e27 Quantitatively speaking, piRNAs far
outnumber miRNAs in the eukaryotic genome, for example,
the human genome contains w 8,400,000 annotated piRNAs
while w 2000 annotated hairpin miRNA precursors, and
w2600 mature miRNA sequences.28e30 As a distinguishing
characteristic, all piRNAs possess 20-O-methylation at the
30-terminus, a unique feature making them distinct from
miRNAs and siRNAs. Moreover, both miRNAs and piRNAs
predominantly target genes different from their origins by
inhibiting translation or enhancing target mRNA degrada-
tion (heterosilencing). In contrast, siRNAs target and
degrade mRNAs transcribed from the same genes they
originated (autosilencing) (Fig. 1b).31
Since the discovery of piRNAs in HeLa cells in 2010, the
role of piRNAs in malignant cells have also emerged.10 This
review article aimed to discuss the activity of piRNAs at the
transcriptional and post-transcriptional levels first followed
by the emerging roles of piRNAs in cancer stemness, drug
resistance, and tumor immunology. Besides, the applica-




As the root of piRNA dysregulation in cancer is likely the
result of disorders in piRNA biogenesis, it is necessary to get
insight into the piRNA biogenesis mechanism first. Recent
studies of flies and mice,32e34 and data from an evolution-
arily broad range of non-model species,35 suggest that
piRNA biogenesis is a highly conserved process, and in most
Figure 1 Characteristics and progression of piRNAs. a, The milestone events in the piRNA field. b, piRNAs show distinct char-
acteristics different from miRNAs and siRNAs, from genome source to RISC formulation and gene silencing style. Abbreviation: EV,
exosome vesicle; MM, Multiple myeloma; PTGS: post-transcriptional gene silencing; PTGA: post-transcriptional gene activation;
TGA, transcriptional gene activation; TGS, transcriptional gene silencing; H3K9me3, trimethylation of H3 lysine 9; UTR, untrans-
lated region; RISC: RNA-induced silencing complex.
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animals the ping-pong and phased piRNA pathways collab-
orate to make complex populations of piRNAs (Fig. 2).
Transcription in nuclear
piRNA clusters are a discrete number of genomic loci that
stood out as hotspots responsible for producing the vast
majority of piRNAs in most species.36 Based on the ability to
generate piRNAs from one or both genomic strands, piRNA
clusters are roughly divided into unistrand and dual-strand
clusters. Both types of piRNA clusters are transcribed by
RNA polymerase II (pol II) (Fig. 2). The products of unistrand
clusters depend on canonical genic transcription units,
especially the conserved transcriptional factor A-MYB, and
will undergo canonical RNA processing in the nucleus, i.e.,
50capping, splicing, and polyadenylation.37e41 On the other
hand, dual-strand piRNA clusters do not possess their own
promoters and are regulated by non-canonical transcrip-
tional mechanisms driven by nuclear transcription factors
including Rhino (Rhi), Deadlock (Del), and Cutoff
(Cuff).38,42e45 In flies, piRNA precursors transcribed from
genomic clusters are capable of targeting transposons for
repression.6 However, in humans, most genomic piRNAs are
derived from human protein-coding genes or long non-
coding RNA (lncRNA) genes rather than transposons, indi-
cating that human piRNAs may have functions beyond
transposon silencing.1,3,41,46,47
Ping-pong cycle
In most animals, piRNA precursors are exported from the
nucleus and localize in the nuage where biogenesis via the
ping-pong cycle takes place (Fig. 2).6,48 In the germ cells of
Drosophila, Argonaute 3(Ago3) and Aubergine ((Aub) play
instrumental roles in the ping-pong cycle. Ago3 is biased
towards a sense strand and adenine at nucleotide 10,
whereas Aub prefers an antisense strand and uridine at
nucleotide 1.6,49 Via their slicer activity, Ago3 and Aub
cleave target RNAs at positions 10 and 11 of the guide
strand, respectively.50 More specifically, a trigger piRNA
will combine with Ago3 and scan all of the transcripts that
exit the nucleus. After identifying a target with a comple-
mentary sequence (antisense), the Ago3/piRNA complex
binds to the precursor transcript and cleaves it, thereby
generating antisense piRNA. The 50-end of the cleaved
transcript then becomes a responder piRNA (antisense) and
binds to Aub. This complex can go on to cleave cluster
transcripts (sense); the sense piRNA product of this cleav-
age event can reinitiate the cycle. In mice, ping-pong cycle
is primarily driven by PIWIL2/MILI and PIWIL4/MIWI2 in pre-
pachytene piRNAs of pre-natal male mice.8,51,52 The ping-
pong signal is also found in bovine, macaque, and human
ovarian or testicular piRNA biogenesis.53 And in fetal human
ovaries, ping-pong cycle may be formed by PIWIL2/HILI and
PIWIL4/HIWI2.53,54
Shuttling process
In Drosophila, pre-piRNAs produced in the nuage/Yb bodies
are then shuttled by Armitage(Armi) to the outer mem-
brane of mitochondria (OMM) for phased production.55,56 At
the OMM, Armi is anchored to a binding platform by Gasz
and Daedalus (Daed).57 Both Gasz and Daed ensure the
proper localization of Armi, proximal to dimerized and
active Zuc. In mice, the shuttling protein might be Moloney
leukemia virus 10 like-1 (MOV10L1), an RNA helicase anal-
ogous to Armi.58e63 Gasz has also been confirmed to be a
component of intramitochondrial cement (IMC) that co-
localizes with MILI, TDRD1, and mouse VASA homolog
(MVH).64,65 In humans, MOV10L1 is a testis-specific isoform
of MOV10. The latter has been reported to colocalize and
interact with Ago1 and Ago2 proteins to mediate miRNA-
guided mRNA cleavage in humans.49,58 There are hints
that MOV10L1 gene polymorphisms are associated with
male infertility in azoospermic men with complete matu-
ration arrest.66 Given the critical role of piRNAs in germ cell
maturation and infertility, there may be an interaction
between MOV10L1 and piRNAs.67 The exact role of MOV10L1
and any cofactors that may shuttle PIWI-piRNA complex
from perinuclear granules to IMC in human piRNA biogenesis
is yet to be confirmed, but certainly warrants further
investigation.
Mitochondria-dependent phased production
After being shuttled to the OMM, long piRNA precursors will
be phased by Zucchini (Zuc)/MitoPLD, a highly conserved
mitochondria-anchored endonuclease responsible for
generating both the 50- and 30-termini of piRNAs.16,68e72 In
Drosophila or mice, Zucchini (Zuc)/MitoPLD could cleave
Figure 2 piRNA biogenesis in Drosophila. Abbreviations: Ago3, Argonaute3; Aub, Aubergine; Armi: Armitage; CH3, depicts a 2-O-
methyl group; Zuc, Zucchini.
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long piRNA precursors approximately every 25 or 40 nt,
producing shorter trailer piRNAs following one another
(Fig. 2).36,57 As this process occurs, Armi helps to unwind
piRNA precursor and PIWI protein helps to position Zuc,
thereby dictating the distinct “phasing” of cleavage.35 In
humans, the mitochondria-based piRNA phased production
process has been experimentally verified.73 HIWI2 is
enriched in the IMC of the primordial follicles of human
oocytes and spermatogonia. Interestingly, HILI is largely
excluded from the IMC by HIWI2, suggesting the specific
subcellular compartmentalization of PIWI proteins in
humans. The exact details of piRNA phased production in
humans is not confirmed, but it is thought that human
MitoPLD is involved. As a member of the Phospholipase D
(PLD) superfamily, human MitoPLD localizes on the
OMM.74,75 Whether or not HIWI2 and MOV10L1 guide human
MitoPLD is undiscovered.
Finally, the piRNAs are subjected to 30 trimming by
nibbler and are 20-O-methylated by Hen1.76,77 These PIWI-
piRNA products are then transferred to the nucleus or
remain in the cytoplasm to exert their effects.
piRNA biogenesis and cancer
A variety of cancers involve ectopic piRNA expression
(Fig. 3). In essence, the ectopic piRNA expressions are
caused by the changes in piRNA biogenesis. Alterations in
piRNA biogenesis promote tumorigenesis mainly through
the following ways:
(1) The ping-pong amplification loop is a post-
transcriptional silencing (PTGS) that combines the
silencing of target mRNAs with piRNA production.36 In
Drosophila and mice, the ping-pong cycle despair
often results in transposon burst.8,36 In humans,
disruption of piRNA biogenesis might result in acti-
vation of oncogenes.78,79
(2) Mitochondria are well known as the powerhouse of
cells for their function of ATP production and suicidal
weapon store for signal transduction.80 The impor-
tance of mitochondrial proteins in piRNA biogenesis,
especially Zuc/MitoPLD, further supports the mito-
chondrial regulation of cellular parameters, and
possibly carcinogenesis.36
(3) Mature piRNAs control target genes via DNA methyl-
ation, histone marker deposition, mRNA decay and
degradation, and protein modification. However, a
disruption in piRNA biogenesis may lead to the dis-
orders of piRNA-mediated transcriptional and post-
transcriptional gene regulation; oncogenes can
escape silencing, while tumor-suppressive genes are
mistakenly silenced.
(4) piRNA biogenesis may be related to cancer stemness.
For example, PIWIL2, an important participant in
piRNA biogenesis, cannot be detected in most normal
adult organs in humans, except in testes, as well as in
a wide variety of tumors.81 These facts suggest that
piRNA biogenesis maybe active in germ cells, quies-
cent in normal tissues, but revive in cancer tissues,
consistent with the changing trend of stemness in the
corresponding states of organisms. In addition,
piRNAs and PIWI proteins are reported to be related
to cancer stem-cell maintenance.82,83 In this regard,
piRNA biogenesis may be involved in cancer stemness.
In summary, piRNA biogenesis is a complex process and
highly conserved in humans. Even modest changes in this
process are expected to influence the piRNA expression
level and cellular function profoundly. The following sec-
tion discusses how the piRNA expression levels are crucial
for cancer development.
PIRNAS and cancer: cause and effect
The first report of the role of piRNAs in cancer occurred in
2010 when piRNAs were discovered in HeLa cells.10 Since
that initial discovery, many publications have attempted to
elucidate the role piRNAs serve in cancer development and
progression (Fig. 3a).20,55,78,79,82e127 Ectopically expressed
piRNAs identified in numerous cancers are shown in Fig. 3a
and Table 1. Many piRNAs, especially piR-823 and piR-651,
have been reported to be dysregulated in various types of
cancers, including but not limited to: breast, stomach,
lung, prostate, bladder, colorectal, kidney, liver, lym-
phomas and leukemias (Table 2).
piRNA dysregulation promotes cancer cell
malignant phenotypes
Tumor-suppressor piRNAs act as defenders against carcino-
genesis by suppressing cell proliferation, increasing
apoptosis, disrupting colony formation, decreasing migration
and invasion abilities, and arresting cell cycles.79,84,100,101,106;
Additionally, xenografts with tumor suppressor piRNA over-
expression have been found to often show a slower growth
rate and exhibit decreased metastasis.84’100,106 Such reports
include cases of increased piR-8014 in human glioblastoma,
piR-36712 in breast cancer (BrCa), piRABC in bladder cancer
and piR-55490 or piR-L-163 in lung cancer.79,84,100,101,106
In contrast, oncogenic piRNAs promote cancer progression
by increasing cell proliferation, inhibiting apoptosis, pro-
moting colony formation and angiogenesis, and enhancing
migration and invasion20,90,91,118,121; Xenografts with onco-
genic piRNA overexpression often show a faster rate of
growth and exhibit increased angiogenesis and metas-
tasis.20,91 Such reports include cases of increased piRNA-823
in multiple myeloma, piR-54265 in colorectal adenocarci-
noma, piRNA-651 in non-small cell lung cancer, and piR-823
or piR-1245 in colorectal cancer (Fig. 3b).20,83,90,91,118,121
Mechanism of piRNA dysregulation and cancer cell
malignant phenotypes
To become functional, mature piRNAs usually have to be
loaded into PIWI to form the RNA-induced silencing com-
plex.128 piRNAePIWI complexes are thought to be primarily
involved in target regulation through four mechanisms:
transcriptional gene silencing (TGS) or activation (TGA) and
PTGS or activation (PTGA). PTGS mechanisms regulate
target transcripts directly through cleavage and require the
catalytic activity of PIWI proteins. The ping-pong cycle is a
4 J.-F. Su et al.
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representative example of PTGS mechanisms.32,129 TGS or
TGA, in contrast, does not require the cleavage activity of
PIWI proteins, although it does require the activity of en-
zymes such as histone-modifying enzymes or DNA methyl-
transferases.129,130 With the contribution of these enzymes,
piRNAePIWI RISC can lead to a change in the mRNA output
indirectly via chromatin remodeling. Thus, piRNAs take part
in many aspects of tumorigenesis, from epigenetic regula-
tion to mRNA degradation and protein modification (Fig. 4).
TGS and TGA by piRNAs via aberrant DNA methylation
Active genes are normally identified by the absence of
promoter DNA methylation with the presence of gene
body CpG methylation. In cancer, the methylation status
Figure 3 Dysregulated piRNAs and their cellular signaling pathways in cancer. a, Ectopically expressed piRNAs in cancers. The
white dots refer to the site of corresponding organs. Among all the piRNAs, piR-651, piR-823, piR-4987, piR-39980, and piR-Hep1
exhibit pan-cancer expression patterns, and they are highlighted by underlines. b, piRNA dysregulation results in the activation
or repression of participating molecules in cellular signaling pathways. This leads to malignant cell phenotypes such as cell pro-
liferation, evading apoptosis, metastasis, invasion, and cell cycle arrest. The positive effect is shown as green line, while the
negative effect is shown as red line. Abbreviation: HNSCC, head and neck squamous cell carcinoma. ARHGAP, Rho GTPase activating
proteins; ERb, Estrogen receptor; CASP3: caspase 3; CDK4, Cyclin dependent kinase 4; DNMT, DNA methyltransferase; CNV, copy
number variation; CXCR4, C-X-C motif chemokine receptor 4; HSP1, heat shock protein 1; HSF1, heat shock transcription factor 1;
HPV, human papillomavirus; ICAM1, intercellular adhesion molecule 1; IL6, interleukin 6; mTOR, mechanistic target of rapamycin
kinase; PTEN, phosphatase and tensin homolog; SEPW1, selenoprotein W 1; STAT3, signal transducer and activator of transcription
3; TDRD1, tudor domain containing 1; TP53, tumor protein p53; MMP, M10 matrix metallopeptidases; VEGF, vascular endothelial
growth factor; VHL, von Hippel-Lindau tumor suppressor.
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Table 1 Summary of altered piRNA expression in cancer.





TCGA Tissue cell serum mice
Breast
cancer
piRNA-36,712 Y SEPW1P, P53,P21
and E-cadherin
Inhibits SEPW1 expression, which may suppress
P53, leading to the upregulated Slug but
decreased P21 and E-cadherin levels.
Prognostic yes yes yes no yes TCGA 84
piR-021285 [ ARHGAP11A Attenuated 50 UTR/first exon methylation of
proinvasive ARHGAP11A gene




piR-932 [ Latexin piR-932 and PIWIL2 may promote metastasis
through Latexin methylation




piR-36026 [ SERPINA1, LRAT Directly interacts with SERPINA1 or LRAT and
induce caspase-3 and PI in the nucleus.








piR-sno75 Y TRAIL, MLL3,
KDM6A.
piR-sno 75/PIWIL1/4 complex upregulates the
transcription of tumor necrosis factor (TNF)-
related apoptosis inducing ligand (TRAIL) by
recruiting H3K4 methylase MLL3 and H3K27
demethylase KDM6A.

















piRABC Y TNFSF4 Inhibit cell proliferation, colony formation,
and promote cell apoptosis by increasing the
expression of TNFSF4 protein






piR-30074 e e Regulating transformation of stem cells Theraputic no no yes no no e 125






piR-1245 [ e An inverse correlation between piR-1245 and a
panel of tumor suppressor genes (predicted)
































































































piRNA-54265 [ STAT3 signaling
pathway
Induce p-STAT3 and BCL-XL, MMP2 and MMP9,
reduce cleaved-CASP9, 3 and 7
Diagnostic
Theraputic




piR-015551 Y e piR-015551 may be generated from LNC00964-








piR-5937 Y e Differentiate between cancer patients and
healthy donors, diagnostic performance in
patients with stage I disease; higher sensitivity
than currently used biomarkers CEA and CA19-
9.





piR-30074 e e Regulating transformation of stem cells Theraputic no no yes no no e 94
Gastric
cancer
93 piRNAs Y e e e yes TCGA 95
7 piRNAs [




Lung cancer piR-34871 [ RASSF1C RASSF1C modulate piRNA through attenuation
of the AMPK pathway, as over-expression of
RASSF1C resulted in reduction of p-AMPK, p21,
and p27 protein levels.







piR-57125 Y e Most significantly associated with distant
metastasis
Prognostic 99
piR-55490 Y mTOR Directly binds to 30UTR of mTOR mRNA and
induce its degradation
Theraputic no yes yes no yes RT-PCR 100
piR-L-163 Y ERM proteins, F-
actin, EBP50
Binds directly to phosphorylated ERM proteins
(p-ERM), which is critical for p-ERM’s binding
capability to filamentous actin (F-actin) and
ERM-binding phosphoprotein 50 (EBP50).




piR-L-138 [ p60-MDM2 piR-L-138 is upregulated by CDDP-based agents
and inhibits apoptosis through direct
interaction with p60-MDM2.
Theraputic no no yes no no RT-PCR 149
piR-30074 e e Regulating transformation of stem cells Theraputic no no yes no no e 28
Leukemia hsa_piR_011186 [ CDKN2B, DNMT1,
Suv39H1, EZH2
hsa_piR_011186 promoted cell-cycle
progression, decreased apoptosis by forming
complex with DNMT1, Suv39H1 and/or EZH2
proteins, which inhibit CDKN2B gene through
modulation of the methylation of DNA and
Diagnostic no no yes no no RT-PCR 126















































































































Table 1 (continued )





TCGA Tissue cell serum mice
histone H3 in its promoter region.
Kidney
cancer
piR-34536 Y e e Prognostic no yes no yes no RT-PCR 102
piR-51810 e e
piR-30924 [ e Associated with tumor recurrence and overall
survival.






piR-32,051 [ e Associated with ccRCC metastasis, late clinical
stage and poor cancer-specific survival.






Glioblastoma piRNA-8041 Y Cellular stress
and survival
pathway
Suppressed the heat shock protein and related
DNAJ Protein chaperone families, MAPK/ERK
signaling pathway proteins; (PREICTED)




piR-598 [ e variant rs147061479 in piR-598 increases
glioma risk by abolishing the tumor-suppressive
function of piR-598









Positively correlated with PIWIL4 and DNMT3L;
negatively relative to RTL by direct binding
interaction; upregulated by PTEN mutation or
NOTCH mutation or downregulated by HNSCC
associated CNVs





piR-266308 [ Alcohol Low expression of piR-58510 and piR-35373
significantly correlated with improved patient
survival. Alcohol consumption may cause
dysregulation of piRNA expression and
upregulation of human PIWIL 4.








Associated with tumor stage, patient survival,
and smoking-altered PIWIL1 protein
expression. correlated with TP53 mutation,
TP53e3p co-occurrence, and 3q26, 8q24, and




























































































is reversed with promoter hypermethylation or genome
hypomethylation (Fig. 4a).131,132 piRNAs are hypothesized
to have the ability to both inactivate tumor suppressor
genes via aberrant promoter hypermethylation and acti-
vate oncogenes via gene body hypomethylation
(Fig. 4a).78,124,133 After direct sequence-specific binding
to target CpG sites, piRNAs recruit methyltransferases
such as DNMT1, DNMT3A, and DNMT3B to the respective
region (Fig. 4a).124,126,133 Since binding of transcription
factors and DNA methylation are mutually exclusive, CpG
methylation in promoter regions by piRNAs has been found
to result in transcriptional repression of tumor suppressor
genes p15 and p16.124,126,134 In terms of hypomethylation
the exact mechanism is still unclear. It is thought to
involve a TET methylcytosine dioxygenase (TET)-depen-
dent manner, as TET in collaboration with transcription
factors may lead to DNA demethylation and thus gene
activation (Fig. 4a).131 Interestingly, piRNA mutations may
contribute to cancer if the variant fails to bind to target
regions and fails to form the piRNA-PIWI-DNMT complex.
The exact roles of piRNA in DNA methylation and hypo-
methylation are worth further investigation.
TGS and TGA by piRNAs via histone modification
The N-terminal of histone proteins undergoes extensive
modifications including but not limited to methylation,
acetylation, phosphorylation, ubiquitination, and SUMOy-
lation.135 Activating histone markers include histone H3
lysine 4 trimethylation (H3K4me3), H3 and H4 acetylation,
and histone H3 lysine 36 (H3K36me2 and H3K36me3). These
activating markers help to shape the three-dimensional
structure of the nucleosome into a euchromatin confor-
mation with open chromatin available for transcription.
Repressive histone markers such as trimethylation of H3
lysine 9 and 27 (H3K9me3 and H3K27me3) create a het-
erochromatin state with condensed chromatin (Fig. 4b).136
piRNA can switch the chromatin conformation freely from
heterochromatin to euchromatin by recruiting different
histone-modifying enzymes. Such enzymes include mixed
lineage leukaemia 3 (MLL3) for H3K4 methylation, sup-
pressor of variegation 3e9 homolog 1 (SUV39H1) for H3K9
methylation, enhancer of zeste homolog 2 (EZH2) for H3K27
methylation, lysine demethylases 1A and 5B (KDM1A and
5B) for H3K4 demethylation, as well as KDM6A for H3K27
demethylation (Fig. 4b).126,137,138 It has been reported that
the piR-011186/Ago3 complex represses the expression of
CDKN2B by recruiting Suv39H1 and/or EZH2 to modify the
methylation levels of H3K9 and H3K27 in its promoter re-
gion.126 On the other hand, by complexing with PIWIL1/4
and subsequently recruiting MLL3 and KDM6A, piR-sno75 is
capable of simultaneously enhancing H3K4 methylation and
H3K27 demethylation, and ultimately upregulates the
expression of tumor necrosis factor (TNF)-related
apoptosis-inducing ligand (TRAIL).137 These observations
demonstrate the flexibility of different piRNA/PIWI com-
plexes in the regulation of gene expression through specific
chromatin modification.
PTGS by piRNAs via mRNA decay or degradation
piRNA-induced repression may be mediated at the PTGS
level via direct binding followed by PIWI protein-mediated
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Table 2 Summary of piRNAs showing pan-cancer expression patterns.
piRNA Cancer Expression Related gene Mechanical points Clinical Utility Sample Type Detection Technique Reference
TCGA Tissue cell serum mice
piR-651 Breast cancer [ Estrogen and
Androgen
Modulated by Estrogen and
Androgen Hormone Levels
Theraputic no no yes no no RT-PCR 114
[ e e Diagnostic no yes yes no no piRNA microarrayRT-
PCR
115
Cervical cancer [ e e Diagnostic no no yes no no piRNA microarrayRT-
PCR
115
Gastric cancer Y e The piR-651 level in gastric
adenocarcinoma was higher




no no no yes no RT-PCR 116
[ e Promote cancer cell growth Diagnostic no no yes no no piRNA microarrayRT-
PCR
115
Hodgkin lymphoma Y e e Diagnostic no yes yes yes no RT-PCR 117
Liver cancer [ e e Diagnostic no no yes no no piRNA microarrayRT-
PCR
115
Lung cancer [ Caspase-3-p17,
cleaved-PARP-1,
Bcl-2





Diagnostic no no yes no no RT-PCR 118
[ e e Diagnostic no no yes no no piRNA microarrayRT-
PCR
115
[ Cyclin D1 and
CDK4
piR-651 induces NSCLC
progression through the cyclin
D1 and CDK4 pathway
Diagnostic
Theraputic
no yes yes no yes RT-PCR 119
[ e promote cell proliferation,
apoptosis, migration and
invasion
Theraputic no no yes no no RT-PCR 120
Mesothelium [ e e Diagnostic no no yes no no piRNA microarrayRT-
PCR
115
Prostate cancer [ Estrogen and
Androgen
Modulated by Estrogen and
Androgen Hormone Levels
Theraputic no no yes no no RT-PCR 114
piR-823 Breast cancer [ Estrogen and
Androgen
Modulated by Estrogen and
Androgen Hormone Levels
Theraputic no no yes no no RT-PCR 114




and transcriptional activity of
HSF1
Theraputic no yes yes no no RT-PCR 121


































































































Y e Inhibited cell growth in vitro
and in vivo.
Theraputic no yes yes no yes piRNA microarray RT-
PCR
122
Kidney cancer [/Y e piR-823 is down-regulated in
tumor tissue, but positively
correlated with worse
outcome, indicating its
complex role in RCC
pathogenesis ([blood serum
and urineYtumor tissue)
Diagnostic no yes no yes no RT-PCR 123
Liver cancer [ Gradually increased from
cirrhosis to low- and high-grade
dysplastic nodules and to
hepatocellular carcinoma
(HCC)
Diagnostic no no yes no no RT-PCR 55




tube formation, and invasion
by enhancing VEGF, IL-6, ICAM-
1, CXCR4 and attenuating
apoptosis. (inhibition of
Caspase-3 activation,
downregulation of Bax, and
upregulation of Bcl2) and
production of ROS and NO
Prognostic
Therapeutic
no no yes yes yes RT-PCR 20
[ DNMT3B Myeloid-derived suppressor
cells confer stem-like qualities




Theraputic no yes yes no yes RT-PCR 83
[ DNMT3A and 3B,
p16INK4A
induce de novo DNA
methyltransferases, DNMT3A
and 3B and inhibit
methylation-silenced tumor
suppressor, p16INK4A.
Theraputic no yes yes no no RT-PCR 124
Prostate cancer [ Estrogen and
Androgen
Modulated by Estrogen and
Androgen Hormone Levels
Theraputic no no yes no no RT-PCR 114
piR-4987 Breast cancer [ e Up-regulated piR-4987
expression was associated with
lymph node positivity
Prognostic no yes no no no piRNA microarray RT-
PCR
88
Multiple myeloma [ e Upregulated in stage III MM
patients compared with
healthy individuals
Diagnostic no yes no no no RT-PCR 124















































































































Table 2 (continued )
piRNA Cancer Expression Related gene Mechanical points Clinical Utility Sample Type Detection Technique Reference
TCGA Tissue cell serum mice
piR-Hep1 Liver cancer [ AKT Promotes cell viability,
motility, and invasiveness by
activation of AKT
phosphorylation
e no yes yes no no RT-PCR 97
Multiple myeloma [ e Upregulated in stage III MM
patients compared with
healthy individuals
Diagnostic no yes no no no RT-PCR 124
piR-39980 Fibrosarcoma Y RRM2 piR-39980 promotes apoptosis
and inhibits proliferation by
repressing RRM2 through direct
targeting at its 30UTR through
extensive sequence
complementary binding
Therapeutic no no yes no no RT-PCR 108
Neuroblastoma [ JAK3 Inhibition of piRNA induces NB
cells senescence by modulating
JAK3 through target binding.
piR-39980 desensitizes the
effect of doxorubicin and
inhibit drug-induced apoptosis.
Theraputic no no yes no no piRNA profiling RT-
PCR
127
Abbreviation: BCL2, BCL2 apoptosis regulator; CDK4, Cyclin dependent kinase 4; CXCR4, C-X-C motif chemokine receptor 4; DNMT, DNA methyltransferase; JAK3, Janus kinase 3; HSP, heat
shock protein; HSF1, heat shock transcription factor 1; VEGF, vascular endothelial growth factor; IL6, interleukin 6; ICAM1, intercellular adhesion molecule 1; MM, Multiple myeloma;




























































































mRNA (Fig. 4c).79,84,86,90,100,109 Typically, piRNAs target the
30-untranslated region (30-UTR) of an mRNA, which may be
attributed to the fact that most human genomic piRNAs are
derived from 30-UTR (Fig. 4c).15,79,84,86,90,100 However, the
coding sequence or 50-UTR has been identified as other
possible binding regions (Fig. 4c).86,90 In mice, a large
increase in the expression of targeted RNAs in PIWIL1 slicer
mutants indicates the piRNA-mediated degradation of
mRNA depends on the slicer activity of PIWIL1. Further-
more, piRNAs can also trigger mRNA deadenylation and
decay in human somatic cells; a similar report has been
made in Drosophila and mice.
Figure 4 Mechanism of piRNAs in cancer. a, TGS or TGA by piRNAs via aberrant DNA methylation: In cancer, the piRNAePIWI
complex represses tumor-suppressor genes (TSGs) via recruiting DNA methyltransferases to the promoter and activates onco-
genes by recruiting TET to the gene body. piRNA variants fail to bind to target regions and to form a piRNAePIWIeDNMT complex,
resulting in gene body hypomethylation and oncogene activation. b, TGS or TGA by piRNAs via histone modification: the
piRNAePIWI complex induces the transformation between heterochromatin (condensed) and euchromatin (open) by recruiting
methyltransferases or demethylases to histones and depositing active (H3K4me3) or repressive histone markers (H3K9me3 or
H3K27me3). c, PTGS by piRNAs via mRNA decay or deregulation: the piRNAePIWI complex recruits the TRAMP complex and leads to
mRNA decay. The piRNAePIWI complex results in mRNA degradation via the slicer activity of PIWI. Whether or not other factors are
needed is unknown. d, PTGS or PTGA by piRNAs via protein modification: piRNA loading induces a conformational change in PIWI
and enhances its interaction with proteasomes, resulting in protein phosphorylation or ubiquitination. Abbreviation: CDS, coding
DNA sequence; DNMT, DNA methyltransferase; H3K9, H3 lysine 9; H3K27, H3 lysine 27; H3K4, H3 lysine 4; KDM, lysine demethylase
6A; PTGS: post-transcriptional gene silencing; PTGA: post-transcriptional gene activation; TF, transcription factor; SUV39H1,
suppressor of variegation 3e9 homolog 1; TET, tet methylcytosine dioxygenase 1; TGA, transcriptional gene activation; TGS,
transcriptional gene silencing; UTR, untranslated region.
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139,140 In CD4 primary T-lymphocytes, piR-30840 binds to
the pre-mRNA intron via sequence complementarity.141
After that, the complex acts together with PIWIL4 and
Ago4 to recruit the Trf-Air2-Mtr4 polyadenylation (TRAMP)
complex to this region. This induces the decay of targeted
pre-mRNA through nuclear exosomes. In this way, piR-30840
significantly downregulates interleukin-4 (IL-4) and subse-
quently inhibits the development of Th2 CD4þ T-lympho-
cytes (Fig. 4c).141 This mechanism portrays the versatility
of piRNA downregulating mechanisms, specifically in post-
transcriptional gene silencing.
PTGS and PTGA by piRNAs via protein modification
Dysregulation of phosphorylation or ubiquitination of pro-
teins is a defining feature of numerous cancers.142 piRNAs
may promote tumor formation in this way by upregulating
the phosphorylation and transcriptional activity of signaling
proteins such as heat shock transcription factor 1 (HSF1),
Akt, or signal transducer and activator of transcription 3
(STAT3).91,97,121,143 piR-Hep1 overexpression in hepatocel-
lular carcinoma (HCC) promotes cell viability, motility, and
invasiveness by inducing AKT phosphorylation and thus re-
sults in augmentation of PI3K/AKT signaling pathway.97 By
binding to the PIWI domain of PIWIL2, piR-54265 facilitates
the formation of the PIWIL2/STAT3/phosphorylated-SRC (p-
SRC) complex, thereby inducing the phosphorylating acti-
vation of STAT3 by p-SRC and promoting malignancy of CRC
cells.91 It has been proposed that the molecular mechanism
may be that piRNA loading leads to a conformational
change in PIWI which enhances its interaction with pro-
teasomes (Fig. 4d).144
Although piRNAs can act as either tumor suppressors or
tumor promoters, the general mechanisms used by piRNA-
mediated inhibition or activation are the following four-
step process. (1) Formation of the PIWI-piRNA complex
because a specific PIWI protein is essential for a functional
piRNA128; (2) Searching and interacting with their specific
targets; (3) Recruiting of specific enzymes such as DNA
methyltransferases and/or histone/protein-modifying en-
zymes129,145; (4) Silencing or activating their targets.
However, there are some exceptions. For example, in
piRNA-mediated mRNA degradation, the PIWI-piRNA com-
plex themselves are fully functional without any additional
enzymes.
Emerging role of PIRNAS in cancer stemness
and drug resistance
Cancer stem cells (CSCs) are regarded as small and unique
sources of cells with self-renewal and differentiation ca-
pacity and can generate a variety of cell types that
constitute a tumor.146 These cells, despite making up a
small proportion of the total number of tumor cells, may
serve as the primary contributors to progression, metas-
tasis, recurrence, and drug resistance.147 In recent studies
researchers have been investigating the role of piRNAs in
cancer stem or stem-like cells and the various mechanisms
they may be involved in. It has been reported that the
expression of piR-932 and PIWIL2 is significantly higher in
breast CSCs which have been induced to Epithelial-to-
mesenchymal transition (EMT) by transforming growth
factor-b1 (TGF-b1).82 Further functional study shows that
the piR-932-PIWIL2 complex depresses the Latexin tumor
suppressor gene via the aberrant methylation of its pro-
moter region CpG island, thus contributing to the progres-
sion of breast cancer.82 In another instance, granulocytic-
myeloid-derived suppressor cells (G-MDSCs) have been
found to confer stem-like properties to multiple myeloma
cells by upregulating piR-823 expression and activating
DNMT3B activation.83 Interestingly, the knockdown of piR-
823 reverses the upregulation of CSC marker genes and
proteins induced by G-MDSCs in multiple myeloma cells.
This suggests that piR-823 is an essential factor in the
maintenance of multiple myeloma stem cells (MMSC)
stemness.
Drug resistance is an important feature of CSCs and one
of the primary reasons for therapeutic failure.148 The bio-
logical functions of piRNAs have been found to play an
important roles in chemoresistance.84,91,149 piR-L-138 in-
hibits apoptosis in lung squamous cell carcinoma cells and
has been shown to provide chemoresistance toward
cisplatin-based chemotherapy via interaction with p60-
mouse double minute 2 homolog (MDM2).149 Additionally,
increased levels of piR-54265 binds to PIWIL2 and activates
STAT3 signaling, thereby conferring chemoresistance to 5-
fluorouracil (5-FU) and oxaliplatin in colorectal cancer
cells.91 A separate study conducted by the same authors
suggests that a lower level of piR-36712 induces chemo-
resistance towards paclitaxel or doxorubicin in breast
cancer.84 piR-39980 decreases the effects of doxorubicin
and inhibits drug-induced apoptosis by modulating Janus
Kinase 3 (JAK3) through target binding.127 Collectively,
piRNAs may play a crucial role in maintaining the stemecell
properties of cancer cells, especially in drug resistance.
The Uncertain Meaning of PIRNAS in tumor
immunology
Studies on the involvement of piRNAs in the mammalian
immune system are few, let alone tumor immunology. The
limited number of reports indicate that piRNAs are abun-
dant in human CD4 primary T-lymphocytes, monocytes or
dendritic cells (DCs), and they play an important role in
regulating gene expression in these highly differentiated
somatic cells.141,150 piR-30840 significantly decreases
interleukin-4 (IL-4) expression via sequence complemen-
tarity and binding to its pre-mRNA intron, subsequently
restraining the development of Th2 T-lymphocytes. The
piR-30840/PIWIL4/Ago4 complex further interacts with the
TRAMP complex, and induces IL-4 decay in nuclear exo-
somes.141 Another study suggests that tRNA-Glu-derived
piRNA [td-piR(Glu)] depresses CD1A transcription by
inducing H3K9 methylation on monocytes/dendritic cells.
The depression can be reversed by IL-4, inhibiting the
biogenesis of td-piR(Glu) and upregulating CD1a molecules.
As CD1a is a specific DC marker responsible for the pre-
sentation of lipid antigen to T-lymphocytes,151 it suggests
that piRNAs can act as a mediator signal for lipid Ag pre-
sentation in monocytes/dendritic cells.150 These novel
mechanisms provide evidence for the importance of piRNAs
in immune cells. Given the impact of immune cells in tumor
progression, piRNAs may contribute to the cancer immune
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system via IL-4 decay or CD1a dysregulation or other un-
identified methods.
Potential clinical applications of PIRNAS in
cancer
Diagnostic and prognostic value of piRNAs
piRNAs have been proven to be effective diagnostic in-
dicators in cancer, and appear to have higher sensitivity
than currently used biomarkers carcinoembryonic antigen
(CEA) and carbohydrate antigen 19e9 (CA 19e9).93,116 Due
to their distinct expression in postoperative and preopera-
tive patients, peripheral blood piRNAs can be applied in
postoperative long term monitoring and disease progres-
sion.93,116 Patients with increased levels of onco-piRNAs or
low levels of tumor-suppressive piRNAs often show worse
progression-free survival (PFS) or overall survival (OS)
correlated with overall unfavorable prognosis.84,90,91,110,102
For example, PFS time and OS time are significantly short-
ened in patients with colorectal cancer (CRC) who have
high piR-54265 levels compared with patients who have low
piR-54265 levels.91 Additionally, piR-36,712 levels contain
an independent prognostic value in breast cancer in that
low levels are associated with worse clinical outcomes,
shorter PFS, and higher rates of axillary lymph node
metastasis.84 These clear pieces of evidence provide sup-
port for the idea that piRNAs are promising indicators for
prognostic value in cancer.
Liquid biopsy of circulating piRNAs
Liquid biopsy is a commonly used technique that has been
developed to detect cancer at an early stage and allows for
tracking of tumor progression over time. In 2011, it was
discovered that piRNAs could be a promising factor of
analysis in liquid biopsy.122 Area under the receiver oper-
ating characteristic curves (AUCs) of piR-651, piR-823, and
combinations of the two were 0.841, 0.822, 0.860 for
gastric cancer detection in that 2011 study.122 Since then, a
variety of circulating piRNAs have been reported as excel-
lent candidates for liquid biopsy of cancer.91,93,102,117
Interestingly, exosomal piRNAs in the serum of cancer pa-
tients have also been quantified and are often more stable
than miRNAs for the protection of PIWI proteins.20 Specif-
ically, a higher level of piRNA-823 has been detected in
extracellular vesicles secreted from multiple myeloma than
from healthy controls and is positively associated with the
stage of the disease. This indicates that the quantification
of piRNAs in exosomes is also an attractive and promising
inquiry.20
Therapeutic targeting of piRNAs
Molecular beacon (MB)-based bioimaging systems, which
simultaneously combine the diagnosis and therapy of can-
cer, have attracted considerable attention in the cancer
theragnosis field. Specific advantages include non-
invasiveness, low cost, easy accessibility, and real-time
quantitative imaging. MBs have also been applied in piRNA
bioimaging.86,87 For example, endogenous piR-36026 in
breast cancer cells has been successfully visualized by using
a double stranded piR-36026 MB labeled with Cy5.5 fluo-
rescent dye and black hole quencher 2 (BHQ2).86 In addi-
tion, the labeled piR-36026 displays a therapeutic response
by binding to endogenous piR-36026 and blocking its hy-
bridization with TSGs serpin peptidase inhibitor, clade A,
member 1 (SERPINA1) and lecithin retinol acyltransferase
(LRAT).86 This results in the upregulation of SERPINA1 and
LRAT followed by caspase-3 activation and eventually
cancer cell death.86
Moreover, labeling piRNA MBs with different Cyanine
(Cy) fluorescent dyes allows the simultaneous visualization
of multiple endogenous piRNAs in a single cell. For
example, the dual transfection of Cy5.5 labeled piR-36026
MB and Cy3 labeled piR-36743 MB allows for the detection
of both piRNAs in breast cancer cells.87 Furthermore, the
quantitative measurement of different Cy5.5 and Cy3 signal
intensities can successfully distinguish between the sub-
types of breast cancer.87 In general, piRNA MBs may be a
potential cancer theragnosis platform that allows for piRNA
visualization, subtype identification, and TSG activation.
piRNA targeted therapy in combination with standard
chemotherapeutic drugs has demonstrated promising anti-
cancer effects in both in vitro and in vivo experiments. Both
in vitro and in vivo trials have achieved greater efficacy in
combined treatment of breast and colorectal cancer cells.
Using a piR-54265 inhibitor (CRC) or a piR-36,712 analog
(BrCa) in combination with chemotherapeutic agents such
as 5-FU, paclitaxel, and doxorubicin were found to be more
efficacious than treating with each agent alone.84,91 In
addition, the combination of piRNA- and miRNA-targeting
particles has been shown to achieve a satisfactory anti-
cancer effect. After incubation with nano-sized complexes
of miRNA-152 and piRNA-30074, CaCo2 colorectal adeno-
carcinoma cells is transformed into CD4þ cells. Increased
levels of apoptotic markers caspase 9 and mechanistic
target of rapamycin kinase (mTOR) and decreased levels of
marker of proliferation ki-67 (MKI-67) has been detected in
these cells.94 The same effect has been observed in A-549
lung adenocarcinoma cells and Girardi heart cells (cervical
cancer combined with right atrium cancer) after incubation
with the piRNA-30074 and antago-miR-155 complex103,125
These findings support the concept that the incorporation
of piRNA-targeting particles with chemotherapy or miRNA-
targeted therapy may lead to new pathways for cancer
treatment research. In the future, additional combination
therapeutic strategies, including the combination of piRNAs
with immunotherapies such as immune checkpoint in-
hibitors [Programmed Death 1 (PD1)/cytotoxicT-lympho-
cyte-associatedprotein4 (CTLA4)], can be designed to
provide novel opportunities for addressing cancer treat-
ment and drug resistance.
Conclusions and future PERSPECTIVES
The last two decades have brought to light the true po-
tential of piRNAs in liquid biopsy, prognosis, prediction of
treatment response, and target therapy in cancer. piRNAs
contribute to carcinogenesis via aberrant DNA methylation,
histone marker deposition, mRNA degradation, and protein
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modification. However, most of the current researches
focus on the downstream effects of piRNA dysregulation,
and only a few studies investigated the upstream factors
that cause piRNA dysregulation. The root of piRNA dysre-
gulation in cancer is likely the result of disorders in piRNA
biogenesis. Although the process of piRNA biogenesis in
Drosophila and mice is well defined, the exact mechanism
in humans remains unclear. Additionally, it is unknown
whether or not piRNA biogenesis relevant proteins, such as
MitoPLD or MOV10L1, is associated with piRNA dysregula-
tion in cancer.
What’s more, if mitochondria-mediated phased produc-
tion is the final stage of piRNA biogenesis, then how do
mature piRNAs return from mitochondria to nucleus to
exert transcriptional regulation? In flies, most of the
mature piRNAs produced on OMM are loaded into Piwi, one
step essential for piRNAs nuclear translocation.16,33,72
piRNA loading triggers conformational change in Piwi and
exposes a nuclear localization signal (NLS) at Piwi’s N ter-
minus which leads to importin-a-mediated transportation
to the nucleus.152 Piwi could also interact with nucleoporin
358 (Nup358) to enter the nucleus.153 In mice, piRNAs are
loaded with MIWI2 and subsequently translocated to the
nucleus.6 In humans, however, the nucleus translocation
mechanism remains elusive. Is PIWI loading necessary for
piRNA nuclear entry in a similar way as in Drosophila and
mice? If so, which protein is involved? It has been reported
that HIWI/HIWI2-piR-sno75 complex could activate TRAIL
gene by recruiting histone methytransferases MLL3 and
KDM6A to its promoter. Since histone modification happens,
it indicates that HIWI/HIWI2 may be relevant to nucleus
import of piRNAs.137 However, the PIWI proteins which
could be detected in nucleus are in the form of HIWI/HIWI2
and HILI.141,154,155 So, HILI may also be related in this pro-
cess. Therefore, more systematic research on piRNA
biogenesis and nuclear translocation machinery in humans
is needed before we could better understand the piRNA
dysregulation in cancer. Only then can we combat cancer
by targeting piRNA imbalance-mediated carcinogenesis.
Despite the well-established PIWI-piRNA pathway during
normal or cancer development, there are emerging hints
that PIWI could function in a piRNA independent way. Li
et al demonstrate that in the absence of piRNAs, human
PIWIL1 plays an oncoprotein role in activating the anaphase
promoting complex/cyclosome (APC/C) E3 complex, which
then results in proteolysis of a critical cell adhesion-related
protein, Pinin, and finally enhances the metastasis of
pancreatic ductal adenocarcinomas (PDACs).156 Another
study also shows that piRNA-unloaded PIWIL1 promotes
gastric cancer through interaction with the UPF1- mediated
nonsense-mediated mRNA decay (NMD) mechanism.
Furthermore, mutating piRNA-binding residues of PIWIL1
does not compromise its oncogenic function. These piRNA-
independent manner of PIWIL1 are consistant with an
earlier report which failed to detected potentially func-
tional piRISCs formed by PIWIL1 and piRNAs in a colon
cancer cell line (COLO205).157 These lines of evidence
support an piRNA-independent manner of oncogenic PIWIL1
in carcinogenesis. More importantly, all these studies un-
cover an unexpected fact, that is piRNAs are barely
detectable in a series of cancer cells.156,157 It raises the
question that whether the previous dysregulated piRNAs
identified in various types of cancer cells are authentic
piRNAs. A recent report indicates that ubiquitous back-
ground of small RNA-sequencing (RNA-seq) data may
contaminate databases and abundant RNA fragments have
sometimes been misinterpreted as piRNAs.158 So the
authenticity of some of the reported somatic and cancerous
piRNAs and their interaction between PIWI proteins deserve
further investigation.
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protein regulates piRNA cluster expression and piRNA pro-
duction in the Drosophila germline. EMBO J. 2011;30(22):
4601e4615.
44. Le Thomas A, Stuwe E, Li S, et al. Transgenerationally
inherited piRNAs trigger piRNA biogenesis by changing the
chromatin of piRNA clusters and inducing precursor process-
ing. Genes Dev. 2014;28(15):1667e1680.
45. Yu B, Cassani M, Wang M, et al. Structural insights into Rhino-
mediated germline piRNA cluster formation. Cell Res. 2015;
25(4):525e528.
46. Ha H, Song J, Wang S, et al. A comprehensive analysis of
piRNAs from adult human testis and their relationship with
genes and mobile elements. BMC Genom. 2014;15(1):545.
47. Williams Z, Morozov P, Mihailovic A, et al. Discovery and
characterization of piRNAs in the human fetal ovary. Cell Rep.
2015;13(4):854e863.
Mitochondria-based biogenesis and functions 17
+ MODEL
Please cite this article as: Su J-F et al., PIWI-interacting RNAs: Mitochondria-based biogenesis and functions in cancer, Genes & Diseases,
https://doi.org/10.1016/j.gendis.2020.09.006
48. Gunawardane LS, Saito K, Nishida KM, et al. A slicer-mediated
mechanism for repeat-associated siRNA 5’ end formation in
Drosophila. Science. 2007;315(5818):1587e1590.
49. Meister G, Landthaler M, Peters L, et al. Identification of
novel argonaute-associated proteins. Curr Biol. 2005;15(23):
2149e2155.
50. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is
mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001;
15(2):188e200.
51. Beyret E, Liu N, Lin H. piRNA biogenesis during adult sper-
matogenesis in mice is independent of the ping-pong mech-
anism. Cell Res. 2012;22(10):1429e1439.
52. Kabayama Y, Toh H, Katanaya A, et al. Roles of MIWI, MILI and
PLD6 in small RNA regulation in mouse growing oocytes.
Nucleic Acids Res. 2017;45(9):5387e5398.
53. Roovers EF, Rosenkranz D, Mahdipour M, et al. Piwi proteins
and piRNAs in mammalian oocytes and early embryos. Cell
Rep. 2015;10(12):2069e2082.
54. Sasaki T, Shiohama A, Minoshima S, Shimizu N. Identification
of eight members of the Argonaute family in the human
genome. Genomics. 2003;82(3):323e330.
55. Rizzo F, Rinaldi A, Marchese G, et al. Specific patterns of PIWI-
interacting small noncoding RNA expression in dysplastic liver
nodules and hepatocellular carcinoma. Oncotarget. 2016;
7(34):54650e54661.
56. Ge DT, Wang W, Tipping C, Gainetdinov I, Weng Z, Zamore PD.
The RNA-binding ATPase, armitage, couples piRNA amplifica-
tion in nuage to phased piRNA production on mitochondria.
Mol Cell. 2019;74(5):982e995. e986.
57. MunafoM,Manelli V,FalconioFA,etal.DaedalusandGasz recruit
Armitage to mitochondria, bringing piRNA precursors to the
biogenesis machinery. Genes Dev. 2019;33(13e14):844e856.
58. Wang PJ, McCarrey JR, Yang F, Page DC. An abundance of X-
linked genes expressed in spermatogonia. Nat Genet. 2001;
27(4):422e426.
59. Zheng K, Xiol J, Reuter M, et al. Mouse MOV10L1 associates
with Piwi proteins and is an essential component of the Piwi-
interacting RNA (piRNA) pathway. Proc Natl Acad Sci U S A.
2010;107(26):11841e11846.
60. Frost RJ, Hamra FK, Richardson JA, Qi X, Bassel-Duby R,
Olson EN. MOV10L1 is necessary for protection of spermato-
cytes against retrotransposons by Piwi-interacting RNAs. Proc
Natl Acad Sci U S A. 2010;107(26):11847e11852.
61. Fu Q, Pandey RR, Leu NA, Pillai RS, Wang PJ. Mutations in the
MOV10L1 ATP hydrolysis motif cause piRNA biogenesis failure
and male sterility in mice. Biol Reprod. 2016;95(5):103.
62. Vourekas A, Zheng K, Fu Q, et al. The RNA helicase MOV10L1
binds piRNA precursors to initiate piRNA processing. Genes
Dev. 2015;29(6):617e629.
63. Zheng K, Wang PJ. Blockade of pachytene piRNA biogenesis
reveals a novel requirement for maintaining post-meiotic
germline genome integrity. PLoS Genet. 2012;8(11),
e1003038.
64. Eddy EM. Fine structural observations on the form and dis-
tribution of nuage in germ cells of the rat. Anat Rec. 1974;
178(4):731e757.
65. Ma L, Buchold GM, Greenbaum MP, et al. GASZ is essential for
male meiosis and suppression of retrotransposon expression in
the male germline. PLoS Genet. 2009;5(9), e1000635.
66. Sarkardeh H, Totonchi M, Asadpour O, et al. Association of
MOV10L1 gene polymorphisms and male infertility in azoo-
spermic men with complete maturation arrest. J Assist
Reprod Genet. 2014;31(7):865e871.
67. Hong Y, Wang C, Fu Z, et al. Systematic characterization of
seminal plasma piRNAs as molecular biomarkers for male
infertility. Sci Rep. 2016;6:24229.
68. Nishimasu H, Ishizu H, Saito K, et al. Structure and function of
Zucchini endoribonuclease in piRNA biogenesis. Nature. 2012;
491(7423):284e287.
69. Pane A, Wehr K, Schupbach T. Zucchini and squash encode
two putative nucleases required for rasiRNA production in the
Drosophila germline. Dev Cell. 2007;12(6):851e862.
70. Voigt F, Reuter M, Kasaruho A, Schulz EC, Pillai RS, Barabas O.
Crystal structure of the primary piRNA biogenesis factor
Zucchini reveals similarity to the bacterial PLD endonuclease
Nuc. RNA. 2012;18(12):2128e2134.
71. Watanabe T, Chuma S, Yamamoto Y, et al. MITOPLD is a
mitochondrial protein essential for nuage formation and
piRNA biogenesis in the mouse germline. Dev Cell. 2011;20(3):
364e375.
72. Mohn F, Handler D, Brennecke J. Noncoding RNA. piRNA-
guided slicing specifies transcripts for Zucchini-dependent,
phased piRNA biogenesis. Science. 2015;348(6236):812e817.
73. Gomes Fernandes M, He N, Wang F, et al. Human-specific
subcellular compartmentalization of P-element induced
wimpy testis-like (PIWIL) granules during germ cell develop-
ment and spermatogenesis. Hum Reprod. 2018;33(2):
258e269.
74. Choi SY, Huang P, Jenkins GM, Chan DC, Schiller J,
Frohman MA. A common lipid links Mfn-mediated mitochon-
drial fusion and SNARE-regulated exocytosis. Nat Cell Biol.
2006;8(11):1255e1262.
75. Zhang Y, Liu X, Bai J, et al. Mitoguardin regulates mitochon-
drial fusion through MitoPLD and is required for neuronal
homeostasis. Mol Cell. 2016;61(1):111e124.
76. Hayashi R, Schnabl J, Handler D, Mohn F, Ameres SL,
Brennecke J. Genetic and mechanistic diversity of piRNA 3’-
end formation. Nature. 2016;539(7630):588e592.
77. Ohara T, Sakaguchi Y, Suzuki T, Ueda H, Miyauchi K, Suzuki T.
The 3’ termini of mouse Piwi-interacting RNAs are 2’-O-
methylated. Nat Struct Mol Biol. 2007;14(4):349e350.
78. Fu A, Jacobs DI, Hoffman AE, Zheng T, Zhu Y. PIWI-interacting
RNA 021285 is involved in breast tumorigenesis possibly by
remodeling the cancer epigenome. Carcinogenesis. 2015;
36(10):1094e1102.
79. Chu H, Hui G, Yuan L, et al. Identification of novel piRNAs in
bladder cancer. Canc Lett. 2015;356(2 Pt B):561e567.
80. Wallace DC. Mitochondria and cancer. Nat Rev Canc. 2012;
12(10):685e698.
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